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DNA double strand breaks in Human T-Cell 
Leukemia Virus Type 1-induced leukemia/
lymphoma
Hicham H Baydoun1, Mathew A Cherian1, Patrick Green3 and Lee Ratner1,2*
Abstract 
Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive and fatal malignancy of CD4+ T-lymphocytes 
infected by the Human T-Cell Virus Type 1 (HTLV-1). The molecular mechanisms of transformation in ATLL have not 
been fully elucidated. However, genomic instability and cumulative DNA damage during the long period of latency is 
believed to be essential for HTLV-1 induced leukemogenesis. In addition, constitutive activation of the NF-κB pathway 
was found to be a critical determinant for transformation. Whether a connection exists between NF-κB activation and 
accumulation of DNA damage is not clear. We recently found that the HTLV-1 viral oncoprotein, Tax, the activator of 
the NF-κB pathway, induces DNA double strand breaks (DSBs).
Results: Here, we investigated whether any of the NF-κB target genes are critical in inducing DSBs. Of note, we found 
that inducible nitric oxide synthase (iNOS) that catalyzes the production of nitric oxide (NO) in macrophages, neutro-
phils and T-cells is over expressed in HTLV-1 infected and Tax-expressing cells. Interestingly, we show that in HTLV-1 
infected cells, iNOS expression is Tax-dependent and specifically requires the activation of the classical NF-κB and JAK/
STAT pathways. A dramatic reduction of DSBs was observed when NO production was inhibited, indicating that Tax 
induces DSBs through the activation of NO synthesis.
Conclusions: Determination of the impact of NO on HTLV-1-induced leukemogenesis opens a new area for treat-
ment or prevention of ATLL and perhaps other cancers in which NO is produced.
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Background
Human T-Cell Leukemia Virus Type 1 (HTLV-1) is the 
etiological agent of adult T-cell leukemia-lymphoma 
(ATLL), an aggressive and fatal malignancy of CD4+ 
T-lymphocytes, for which an effective treatment is not 
yet available. HTLV-I is the only transmissible retrovi-
rus that causes cancer in humans. HTLV-1 can be trans-
mitted sexually, by intravenous drug abuse or vertically 
through breast-feeding. Approximately, twenty million 
individuals worldwide are infected with HTLV-1 [1], 
and 2–5% of infected individuals develop ATLL after a 
long period of latency, typically forty or more years. It is 
widely believed that during the period of latency a num-
ber of oncogenic events accumulate and lead to the trans-
formation of infected lymphocytes [2, 3].
The oncogenic events leading to ATLL are largely 
unknown and are under active investigation. Although 
several HTLV-1 viral proteins play a role in viral patho-
genesis, the HTLV-1 encoded oncoprotein Tax provides 
the major contribution to the leukemogenic process 
[4]. Tax perturbs multiple T-cell proliferation pathways, 
including the NF-κB, JAK/STAT, PI3K/AKT and TGF-β 
pathways [5–11]. Tax also inhibits tumor suppressors, 
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induces genomic instability and activates angiogenesis. 
Furthermore, Tax expressing T-cells, which are able to 
induce tumors in vivo and to form colonies in vitro [11–
13], reveal a massive alteration in gene expression, sug-
gesting that Tax regulates a large number of genes. Yet, 
the genes directly affected by Tax have not been com-
pletely characterized [14, 15].
Nitric oxide (NO) is an important cellular signaling 
molecule involved in many physiological and patho-
logical processes. It is generated from l-arginine by the 
various isoforms of nitric oxide synthase (NOS). Consti-
tutively expressed endothelial NOS (eNOS) and neuronal 
NOS (nNOS) synthesize NO and are involved in vasodil-
atation and neuronal communication, respectively. How-
ever, inducible NOS (iNOS) is synthesized de novo in 
response to a variety of inflammatory mediators [16]. 
Cytokines and chemokines activate the expression of 
iNOS, which catalyzes the production of large amounts 
of NO in activated T-cells, and macrophages. Inducible 
NO is the precursor of the highly reactive nitrogen spe-
cies peroxynitrite (ONOO−), an obligatory factor in oxi-
dative DNA damage. NO also induces nitrosative stress, 
apoptosis, mitochondrial damage, cytostasis, and cytoly-
sis [17, 18]. However when produced at low concentra-
tions by macrophages or activated T-cells during chronic 
inflammation, it promotes tumor cell proliferation, 
migration, invasion, and resistance to apoptosis [19]. 
Thus, inducible NO belongs to a category of molecules 
that imposes a critical balance between pro and anti-
apoptotic mechanisms during cancer development. To 
date, drugs targeting NO abundance in mouse models of 
colon, breast and ovarian cancers dramatically decreased 
tumor progression [20–25].
We recently showed that the HTLV-1 Tax protein 
induces DNA double strand breaks (DSBs) [26], the 
most detrimental form of genetic damage, due to inhibi-
tion of transcription, replication and chromosome seg-
regation. In the present study, we found that HTLV-1 
infected T-cells and Tax expressing cells exhibit high 
levels of intracellular NO. Since NO, and its product 
peroxynitrite, are highly reactive molecules that inflict 
DNA damage, we hypothesized that the HTLV-1 Tax 
protein induces DSBs through the induction of NO syn-
thesis. Here we demonstrate that Tax specifically induces 
DSBs through the expression of iNOS via activation of 
the NF-κB and JAK/STAT pathways. In a recent work, 
Tax has been shown to impair DNA replication forks 
and increase DNA breaks. The authors included experi-
ments in which Tax induced breaks by NO through the 
NF-κB pathway [27]. However, those experiments were 
carried out only in the epithelial 293T cell line that does 
not express NOS genes [28, 29]. In addition, a non-selec-
tive drug (L-NMMA) was used in that study to inhibit 
NO release, but more specific drugs to iNOS or genetic 
knockdown experiments were not utilized. Lastly, those 
experiments did not include Western blot or immuno-
fluorescence staining for γ-H2AX which are standard 
evaluations of DNA breaks. By inducing DNA damage, 
NO could be a key player in the onset and progression of 
HTLV-1 induced leukemia.
Results
HTLV‑1 transformed T‑cells display high levels of nitric 
oxide
Nitric oxide is a key component of reactive nitro-
gen intermediates, which constitute major sources of 
DNA damage during chronic inflammation. They are 
involved in the initial events of tumorigenesis as well as 
in inflammatory responses involved in cancer immunity 
[30]. Our cancer model, HTLV-1 induced leukemia, is a 
hematopoietic malignancy characterized by constitu-
tive activation of the NF-κB pathway that drives a potent 
inflammatory response [6, 31]. In order to investigate the 
mechanisms by which NO affects genomic instability in 
this model, we first evaluated the concentration of NO 
in a variety of human HTLV-1 transformed T-cell lines: 
MT2, MT4, and HuT102. We used the human T-ALL 
cell lines, Jurkat and CEM, as controls. The staining 
of the intracellular pool of NO in these cell lines using 
4,5-Diaminofluorescein Di-acetate (DAF-2DA) showed 
that HTLV-1 transformed T-lymphocytes display high 
levels of intracellular NO when compared to control cell 
lines (Fig.  1a, b first column). In activated T lympho-
cytes, the inflammatory response induces the expression 
of inducible nitric oxide synthase (iNOS) which consti-
tutes the main source of nitric oxide production. Treat-
ment of HTLV-1  infected cells for 48  h with a selective 
inhibitor of iNOS (1400 W), inhibited NO production by 
~40%, indicating that iNOS was at least partially respon-
sible for production of NO in HTLV-1 transformed cell 
lines (Fig. 1a, b second column). An increase of 1400 W 
concentration could not potentiate its inhibitory effect, 
suggesting that NO is still produced in the cells. How-
ever, the treatment of HTLV-1 infected cells for 24 h with 
a NO scavenger, such as cPTIO, reduced the amount of 
NO by 90% indicating the specificity of NO staining by 
DAF-2DA (Fig. 1b, third column).
iNOS expression in ATLL cells has previously been 
reported [32, 33]. We verified these observations, using 
real time RT-PCR to demonstrate that MT4 and Hut102 
cells express significantly higher levels of iNOS mRNA 
than control CD4+, Jurkat and CEM T cells (Fig. 1c). In 
addition, RNA was extracted from PBMC samples of 
patients with acute ATLL (patients 1, 2 and 3, Table  1). 
All three ATLL samples showed activation of iNOS 
expression when compared to the level detected in 
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control cells (Fig.  1c). To determine if the elevation of 
iNOS expression in HTLV-1 infected cells and in ATL 
samples was due to HTLV-1 viral infection, we measured 
iNOS expression in freshly infected PBMC with HTLV-1 
virus. We co-cultured PBMCs from a healthy donor with 
irradiated MT2 cells (ratio 10–1) for 17 days and meas-
ured the expression of iNOS mRNA. After 17  days in 
culture, irradiated  MT2 cells and non-infected PBMC 
expressed very low levels of iNOS when compared to 
non-irradiated MT2  cells. However, the freshly infected 
PBMCs expressed a comparable level of iNOS as that 
found in non-irradiated MT2 cells (Fig.  1d). In freshly 
infected PBMCs, we also detected by immunofluores-
cence the expression of HTLV-1 p24 gag protein as an 
indication of viral infection (Fig. 1e).
As expected, the protein level of iNOS was increased in 
HTLV-1 positive MT4 and HuT102 transformed cell lines 
as compared to control PBMC and CD4+ cells (Fig. 1f ). 
Intracellular fluorescence staining was also performed to 
determine the localization of iNOS. Images presented in 
Fig. 1g indicate that iNOS is expressed in more than 90% 
of MT4 cells, but it is absent from control CEM T cells. 
iNOS was localized in the cytoplasm of MT4 cells in an 
aggresome distribution, as previously described [34].
To determine if elevated levels of iNOS in MT4 cells 
were responsible for the high level of NO, we estab-
lished stable MT4 cell lines that express a TetOn induc-
ible shRNA to downregulate the expression of a control 
gene (GFP) or that of iNOS. MT4-TetOn GFP shRNA 
and MT4-TetOn iNOS shRNA  cells were induced by 
doxycycline for 48  h and iNOS protein expression was 
assessed by Western blot. Figure  1h showed complete 
depletion of iNOS expression in MT4 cells expressing 
specific shRNA against iNOS mRNA as compared to 
MT4 cells expressing control shRNA. Similarly, the pro-
duction of nitric oxide was completely reduced in MT4-
TetOn iNOS shRNA expressing cells, when compared to 
MT4 expressing control shRNA (Fig. 1i), indicating that 
iNOS is the major enymatic catalyzer of nitric oxide pro-
duction in HTLV-1 transformed cell lines. The depletion 
experiment and the related reduction in NO production 
also suggested that 1400 W may not be sufficiently active 
to completely inhibit iNOS activity. Similar results were 
obtained with less selective drugs such as L-NMMA and 
L-NIL (data not shown).
iNOS induces DNA double strand breaks (DSBs)
Since NO is an obligatory factor in oxidative DNA dam-
age, we wanted to determine whether iNOS induces 
DSBs through NO synthesis. Induction of DSBs gener-
ates a DNA damage response orchestrated by the mas-
ter regulator ATM (Ataxia Telangiectasia Mutated) that 
activates a cascade of effectors to repair the DNA defects. 
ATM-mediated phosphorylation at serine 139 of the 
histone H2AX protein (γ-H2AX) is the critical step to 
mark the DNA damage sites and leads to the formation 
Table 1 Patient characteristics
ATLL subtype, Shimoyama classification; BM, bone marrow % malignant cell; Ca, calcium (mg/dL, 8.5–9.9 normal); CD3, CD4 or CD25 (K/cumm); LDH, lactate 
dehydrogenase (U/L, normal <250); nd, not determined; PVL, proviral load (copies/100 PBMCs); stage, Ann Arbor lymphoma stage; wbc, white blood cell count  
(K/cumm).
Pt # ATLL Subtype Stage Wbc CD3 CD4 CD25 LDH Ca BM PVL
1 Acute IV 135.7 119 119 67 550 14.1 81% 145.4
2 Acute IV 20.6 6.3 6.4 5.9 1,269 10.1 59% 77.3
3 Acute IV 69.4 65.2 63.1 nd 1,496 9 nd 88.4
(See figure on previous page.)
Fig. 1 High levels of NO and iNOS are detected in HTLV-1 transformed cell lines and ATLL patients’ samples. a HTLV-1 transformed cell lines MT2, 
MT4, and HuT102, and transformed human T-cell controls Jurkat and CEM treated with DMSO or with 1400 W, an iNOS selective inhibitor, were 
stained with DAF-2DA to measure the intracellular pool of NO. The histograms represent the average of three different experiments with the indi-
cated standard deviations. b Flow cytometry analyses of the intracellular pool of NO shows the difference between control cells and HTLV-1 infected 
cell lines (1st column), HTLV-1 infected cells untreated or treated with iNOS inhibitor, 1400 W (2nd column), and HTLV-1 infected cells untreated or 
treated with NO scavenger, cPTIO (3rd column). c qRT-PCR of the intracellular pool of iNOS mRNA showed a specific increase in HTLV-1 infected cells 
and in ATLL patients’ samples but not in the control CD4+, Jurkat, and CEM cells. GAPDH was used as an internal control for mRNA quantification. d 
Real-time measurement of iNOS mRNA of freshly infected PBMCs with irradiated MT2 cells. iNOS mRNA pool is shown in irradiated MT2 cells alone, 
non-irradiated MT2 cells, and in uninfected PBMCs at 17 days of infection. e Immunoflurescence staining of Gag protein, p24, and iNOS in MT2 and 
freshly infected PBMC at 17 days of infection. f Western blot analysis of iNOS protein expression shows the expression of iNOS in MT4 and HuT102 
cell lines but not in the control PBMC or CD4+ primary cells. g Immunofluorescence staining of iNOS protein in CEM control cells and in HTLV-1 
transformed human MT4 cells. h MT4 cells expressing inducible TetOn control shRNA (GFP) or TetOn shRNA directed against iNOS mRNA were estab-
lished, and iNOS expression was measured by Western blot. i NO measurement by DAF-2DA showing that depletion of iNOS expression by shRNA 
reduces completely the production of NO.
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of γH2AX foci [35]. ATM also phosphorylates and acti-
vates a set of sensors and effectors involved in DNA 
repair, which are gradually recruited to γH2AX foci. To 
determine the effect of iNOS inhibition on the formation 
of γH2AX foci, we stained iNOS and pH2AX proteins 
in MT4 cells with specific antibodies (Fig.  2a). In addi-
tion, MT4 cells treated for 48 h with the iNOS inhibitor, 
1400  W, were also examined by immunofluorescence 
microscopy. Immunofluorescence images showed that 
inhibition of iNOS activity was associated with a decrease 
in the number of DSB foci stained with γH2AX (Fig. 2a, 
b). To quantify the effects of iNOS inhibitor, the number 
of DSB foci was measured in 100 cells, and demonstrated 
a decrease of 60% in MT4 cells treated with iNOS inhibi-
tor when compared to untreated MT4 cells (Fig. 2b). We 
also examined effects on the number of γH2AX foci in 
MT4 expressing shRNA against iNOS mRNA by the 
TetOn inducible system. Expression of the iNOS shRNA 
markedly reduced the number of γH2AX foci (Fig.  2c, 
last row). However, the expression of control shRNA in 
MT4 cells had no effect on the number of γH2AX foci 
(Fig. 2c).
The DNA damage response was also assessed by West-
ern blot using specific antibodies that recognize different 
phospho-proteins of the DNA damage response, includ-
ing ATM, ATR (ataxia telangiectasia and Rad3-related 
protein), 53BP1 (p53 binding protein 1), the cell cycle 
delay checkpoint protein Chk2, and p-H2AX. The blot 
results were consistent with those obtained with fluo-
rescent microscopy and showed a reduction of the DNA 
damage response in MT4 cells in which iNOS was almost 
completely depleted by shRNA. MT4 cells expressing 
control shRNA retained a high level of pATM, pATR, 
p53BP1, pH2AX, and pChk2 (Fig.  2d). Of note, the 
western blot results showed that iNOS expression was 
also depleted in MT4 cells in which the TetOn system 
expressing shRNA against iNOS mRNA was not induced 
by doxycycline. This observation was due to the leakiness 
of the TetOn system and the fact that MT4 cells were not 
maintained in tetracycline-free media to keep the TetOn 
system functional. Consistently, the reduction of  the 
DNA damage response correlated with the decrease 
in iNOS expression. The mono and poly-ubiquitinated 
forms of H2AX that play a critical role in H2AX Ser-139 
phosphorylation (γH2AX), and facilitate the recruitment 
of other factors to DNA damage foci [36] were detected 
in MT4 cells expressing control shRNA but not in MT4 
cells expressing iNOS shRNA (data not shown). The cor-
relation between iNOS depletion and the decrease of the 
DNA damage response was also observed in HuT102 
cells (data not shown), another HTLV-1 transformed 
cell line, indicating that DSB induction by iNOS is spe-
cific, and is not cell line dependent. Taken together, these 
results indicate that inducible NO synthesis constitutes 
an important source of DNA damage in HTLV-1 infected 
cells. Neither inhibition of iNOS activity, or depletion 
of iNOS expression had an effect on the viability of cells 
(data not shown) as measured by Annexin V and pro-
pidium iodide staining, suggesting that apoptosis was not 
affected under those conditions.
For functional evaluation of the effect of iNOS inhibi-
tion on the induction of DNA damage in HTLV-1 trans-
formed cells, we used the comet assay, alkaline method, 
which is a single cell electrophoresis technique that 
detects both single-strand and double-strand breaks. NO 
and its reactive product (ONOO−) induce DNA modi-
fications that start as single-strand breaks (SSB) which 
then lead to the formation of double-strand breaks (DSB). 
The comet tail was scored according to DNA content, by 
measuring integrated fluorescence intensity. We used the 
object count module that is available in the microscope 
NIS elements software to measure the length, area, and 
intensity of tails (DNA migration), and calculated DNA 
damage parameters (Fig.  2e, f ). At least 100 randomly 
selected cells were analyzed per sample. As expected, 
MT4 cells expressing control shRNA, which retain high 
levels of iNOS migrated with relatively long tails (Fig. 2e, 
first panel and f ). The depletion of iNOS expression by 
the TetOn-shRNA system showed a reduction in tail 
area of comets (Fig.  2e, second panel and f ). Likewise, 
treatment of MT4 with NO scavenger, cPTIO, for 48  h 
reduced p-H2AX expression by 75% confirming that NO 
is the major source of damage to DNA in the HTLV-1 
infected cells (Fig. 2g).
HTLV‑1 Tax protein activates the expression of iNOS
Since HTLV-1 Tax is an activator of T-cell proliferation 
pathways, we wanted to determine whether Tax was 
involved in the activation of iNOS expression. We used 
JPX9 and TetOn-Tax human Jurkat T-cell lines that con-
tain stable inducible systems for the expression of Tax 
with CdCl2 [37] and doxycycline [38], respectively. Tax 
was induced for 24 h or 48 h, and Western blot was per-
formed using anti-iNOS and anti-Tax specific antibodies. 
The results showed a specific increase of iNOS expres-
sion when Tax was induced (Fig.  3a). These findings 
indicate a dose-dependent correlation between Tax and 
iNOS expression. Of note, the reagents used to induce 
Tax expression had no effect on iNOS expression since 
Jurkat control cells treated with CdCl2 did not show 
iNOS expression (Fig. 3a).
We next evaluated the DNA damage response 
(p-H2AX and p-Chk2) in Tax inducible cell lines, with or 
without treatment with an iNOS inhibitor. We previously 
showed that induction of Tax in JPX9 cells was associated 
with an increase in the DNA damage response [26]. In 
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Fig. 2 iNOS inhibition is associated with a reduction of the DNA damage response. a Double immunofluorescence staining of MT4 cells treated 
with or without iNOS inhibitor, 1400 W (7 nM), for 48 h, using specific primary antibodies directed against iNOS, and γ-H2AX marker of DSBs and fol-
lowed by secondary antibodies conjugated to Alexa fluor 488 (green for iNOS) and Alexa fluor 596 (red for γ-H2AX), respectively. DAPI dye was used 
to stain the nucleus of the analyzed cells. b The histograms represent an accurate estimation of the number of DSBs foci in MT4 cells and MT4 cells 
treated with iNOS inhibitor. c The same double immunofluorescence staining was also carried out on MT4 cells expressing doxycycline inducible 
TetOn control shRNA or MT4 inducible TetOn shRNA directed against iNOS mRNA. d MT4 cells that express inducible TetOn-shRNA control or shRNA 
specifically targeting the mRNA of iNOS were not induced or induced for 48 h with doxycycline and blotted for iNOS, p-H2AX, H2AX, pChk2, Chk2, 
p-ATM, p-ATR, p35BP1 and HSP90 as an internal control. Hsp90 blots are shown for each set of separately loaded cell lysates. * non-specific band. e 
Comet alkaline assay method that detects DNA breaks was used for evaluation of DNA damage in the same cells tested above. f The object count 
module was used to measure the area of comet tails (DNA migration), and calculate DNA damage parameters. At least 100 randomly selected cells 
were analyzed per sample. g Western blot on the extracts of MT4 cell untreated or treated with cPTIO (NO scavenger) using p-H2AX and total H2AX 
antibodies.
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this context, the inhibition of enzymatic activity by iNOS 
inhibitor, 1400 W, was associated with a reduction in the 
DNA damage response (Fig. 3b). We observed a decrease 
of p-Chk2 and p-H2AX in the TetOn-Tax cells treated 
with 1400 W (Fig. 3b). Cells treated with iNOS inhibitor 
expressed the same level of iNOS protein (Fig.  3c), but 
NO production was decreased (Fig.  3c). Thus, NO pro-
duction correlated with the DNA damage response.
Fig. 3 HTLV-1 Tax specifically induces the activation of iNOS expression. a Tax inducible cell lines JPX9 and TetOn-Tax were induced for 48 h with 
CdCl2 (40 μM) and doxycycline (500 ng/ml) for 24 and 48 h respectively, to express the Tax protein. Cell extracts were subject to Western blot analy-
sis using antibodies against iNOS, Tax and actin. b Doxycyline-induced TetOn-Tax cells were left untreated or treated with 1400 W (7 nM) for 48 h. 
Western blots were performed on the cell extracts by using anti-p-H2AX, anti-pChk2, anti-H2AX, anti-Chk2, and anti-iNOS antibodies. The percent-
age of expression of DNA damage response after iNOS inhibition was quantified by the ratio of phosphoprotein on the total amounts of proteins, 
and it was indicated underneath the Western blot. * non-specific band. c NO staining with DAF-2DA was performed on two experiments in which 
TetOn-Tax was induced and cells treated with iNOS inhibitor, 1400 W, to show that the reduction in DNA damage response was associated with a 
relative decrease in NO production. d, e Real time PCR of iNOS and IκBα mRNA in negative control CD4+ and Jurkat cells, in HTLV-1 transformed cell 
lines MT4 and HuT102, and in three Tax-negative ATL cell lines, MT1, ED4505- and TL-Oml1.
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The role of Tax in maintaining the ATL phenotype 
remains an elusive question because of the existence of 
Tax-negative ATL cell lines [39, 40]. We wanted to deter-
mine whether the expression of Tax in ATL is a prerequi-
site for iNOS expression. The measurement by real time 
PCR of iNOS mRNA expression in three Tax-negative 
ATL cell lines, MT1, ED4505- and TL-Oml1 showed 
no expression of iNOS mRNA when compared to nega-
tive control CD4+ and Jurkat cells (Fig. 3d). Surprisingly, 
the expression of IκBα, which is a target gene of NF-κB 
transcription factors, was not detected in Tax-negative 
ATL cell lines and control CD4+ and Jurkat cells, but 
was positive in MT4 and HuT102, indicating that NF-κB 
activation is required for induction of iNOS expression 
(Fig. 3e). It has been previously shown that activation of 
CD4+ cells and macrophages results in the expression of 
iNOS [41, 42]. Our experiments showed that the com-
bination of LPS with IFNγ or TNFα with IFNγ induces 
NO production in control CEM cells as well as in THP1 
differentiated cells but not in HTLV-1 infected MT4 cells 
because they were already saturated (data not shown).
Tax activates iNOS expression through the NF‑κB pathway
We next explored the mechanism of Tax activation of 
iNOS expression in HTLV-1 infected cells. Since there is 
considerable literature on Tax activation of NF-κB, and 
NF-κB activation of iNOS [43–46], we first assessed the 
role of the NF-κB pathways in Tax activation of iNOS. 
Two pathways drive NF-κB induced transactivation. 
The p50/RelA and p52/RelB dimers are primary com-
ponents of the classical and the alternative NF-κB path-
ways, respectively. To determine which NF-κB pathway is 
involved in iNOS activation, we used a reporter construct 
in which the expression of  a luciferase reporter gene is 
driven by the human iNOS-promoter (phiNOS-Luc) 
[47]. We co-transfected 293T cells with phiNOS-Luc and 
with vectors expressing S-tag-Tax1 of HTLV-1 or S-tag-
Tax2 of the related virus, HTLV-2. While Tax1 activates 
both NF-κB pathways, Tax2 exclusively activates the clas-
sical NF-κB pathway [48]. The luciferase activities meas-
ured after 48 h of transfection showed that both Tax1 and 
Tax2 were able to activate the iNOS promoter when com-
pared to those measured in the control, transfected cells, 
suggesting that the classical NF-κB pathway is sufficient 
to activate iNOS expression (Fig.  4a). Expression of the 
S-tag-Tax1 M22 mutant, which is completely defective in 
NF-κB activation, showed no activity on the iNOS pro-
moter, suggesting that NF-κB activation induces iNOS 
expression in HTLV-1 infected cells (Fig. 4a). A Western 
blot analysis was performed on the same cell extracts, 
showing that S-tag-Tax1, S-tag-Tax2, and S-tag-Tax1 
M22 were expressed in the transfected cells (Fig. 4b). The 
Western blot in Fig.  4b also shows specific processing 
to p52 of the p100 alternative NF-κB subunit in cells-
expressing Tax1, confirming the functional activation 
of the alternative NF-κB pathway by Tax1 but not Tax2 
and Tax1 M22. In addition to NF-κB activation, Tax1 is 
known to transcriptionally activate HTLV-1 viral expres-
sion through the ATF-CREB pathway. To determine if 
the ATF/CREB pathway is critical in iNOS activation by 
Tax, we co-transfected 293T cells with phiNOS-Luc and 
with vectors expressing S-tag-Tax1 or S-tag-Tax1 M47 
mutant, which is completely defective in the ATF/CREB 
activation (Fig. 4c). The luciferase activities showed that 
the ability to activate the expression of iNOS by Tax1 
M47 was similar to that induced by Tax1 wild type, indi-
cating that ATF/CREB was not involved in iNOS acti-
vation. The activation effect of iNOS promoter by Tax 
proteins was also confirmed by co-transfection of the 
same Tax expressing vectors with phiNOS-Luc reporter 
plasmid in Jurkat cells, indicating similar activation in T 
cells, the physiological host of HTLV-1 infection (Fig. 4d). 
In addition, the expression of Tax1, Tax2 and Tax1 M22 
in cells-cotransfected with κB-Luc reporter plasmid, a 
promoter responsive to the classical NF-κB pathway, 
showed that Tax1 and Tax2 but not Tax1 M22 were able 
to activate the expression of κB-Luc, indicating that both 
wild type proteins were functionally active (Fig. 4e).
For further investigation of the specificity of iNOS acti-
vation, we made stable Hela cell lines that constitutively 
express either control shRNA or specifically targeted 
shRNA, to deplete the expression of p105 or p100 of the 
classical and alternative NF-κB pathways, respectively. 
The shRNAs were successful in reducing the expression 
of p105 and p100, as well as the processed p50 and p52 
products, respectively (Fig.  4f, g). Transfection of these 
Hela cells with the κB-Luc reporter plasmid showed that 
κB-Luc activity is exclusively decreased when p105 was 
depleted, confirming that κB is activated by the classi-
cal pathway (Fig. 4h). Transfection of the same cells with 
phiNOS-Luc reporter plasmid showed that shRNA to 
p105 or p100 decrease iNOS activation, indicating that 
both NF-κB pathways contribute to iNOS activation 
(Fig. 4I).
Tax‑mediated iNOS expression also requires activation 
of the JAK/STAT pathway
In addition to the NF-κB transcription factors, IFNγ was 
described as a key cytokine involved in iNOS expres-
sion. IFNγ is a type II interferon that activates the JAK/
STAT pathway, a major signaling pathway involved in the 
regulation of the immune response. JAK/STAT induces 
an ensemble of interferon-stimulated genes including 
IRF-1, which has been shown to cooperate with NF-κB 
transcription factors to induce the expression of iNOS 
in melanomas [49]. We first checked the expression of 
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Fig. 4 Tax activates iNOS expression through the NF-κB pathway. a A functional test showing the direct effect of Tax on iNOS expression. 293T cells 
were cotransfected with phiNOS-Luc along with vectors expressing S-tag control, S-tag Tax1, S-tag Tax2 or S-tag Tax1 M22 mutant. The transfec-
tion also included TK-RL to serve as a control of transfection. 48 h later, the luciferase activities were measured in the cell extracts. The histograms 
represent the average of three different experiments with the indicated standard deviation. b Western blot analysis showing that Tax1 but not Tax1 
M22 protein analyzed in (a) was functional and able to process the p100 NF-κB2 protein to the p52 subunit using a specific anti-p100 antibody. c 
Similar transfection as in (a) was carried out on 293T cells with phiNOS-Luc and the vectors expressing S-tag control, S-tag Tax1, or S-tag Tax1 M47 
mutant. d The effect of Tax on iNOS expression was also carried out in T cells (Jurkat), the physiological host of HTLV-1 infection, showing similar 
activation as shown in (a). e In parallel, 293T cells were co-transfected with κB-Luc reporter plasmid along with the same set of vectors used in (a) to 
show that Tax1, Tax2 but not Tax1M22 were able to activate the classical NF-κB pathway. f, g Stable Hela cells that express specific shRNA directed 
against mRNA of p105 and p100 were analyzed by Western blot using respectively specific anti p50 and anti p100 antibodies. h The same Hela cells 
were co-transfected either by κB-Luc reporter plasmid and induced by TNFα (1 ng/ml) and lymphotoxin α1/β2 (1 ng/ml) to induce the classical and 
alternative NF-κB pathways or i by phiNOS-Luc plasmid with the Tax-expressing vector to activate both NF-κB pathways. The expression of κB-Luc 
was inhibited with the depletion of p105. However, phiNOS-Luc expression was inhibited when either p105 or p100 were depleted.
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IRF-1 in different cell lines, including control Jurkat, 
CEM, non-induced, and induced TetOn-Tax Jurkat cells. 
Interestingly, IRF-1 was induced when Tax expression 
was induced by doxycycline (Fig. 5a). Detection of lower 
levels of IRF-1 in TetOn-Tax Jurkat cells not treated with 
doxycycline, is likely due to leakiness of this cell line.
We next compared the activation of the JAK/STAT 
pathway in control CEM, non-induced JPX9, CdCl2-
induced JPX9, and MT4 cells. Only Tax expressing cells, 
demonstrated an increase of p-JAK1 and IRF-1, indicat-
ing an activation of the JAK/STAT pathway (Fig. 5b) with 
Tax expression. We also observed a specific increase of 
p-JAK1 and p-STAT1 but not p-Tyk2 (activated only by 
type I interferon) in induced TetOn-Tax Jurkat cells sug-
gesting a specific type II interferon activation of JAK/
STAT (Fig. 5c). Although a general interferon response is 
induced after viral infection, HTLV-1 has evolved strate-
gies to neutralize the interferon response. It has recently 
been shown that SOCS1 protein (Suppressor of cytokine 
signaling 1) is specifically induced by Tax to inhibit the 
interferon response [50]. SOCS1 is also induced by the 
interferon signaling pathways, but the mechanism and 
factors involved in its activation were not completely 
elucidated. To determine if SOCS1 induces a negative 
effect on iNOS expression, we transfected MT4 cells 
with either a control siRNA or a specific siRNA directed 
against SOCS1 mRNA and measured the mRNA pool of 
both SOCS1 and iNOS. The siRNA successfully inhibited 
more than 70% of SOCS1 expression. However, iNOS 
expression in MT4 cells transfected with SOCS1 siRNA 
was slightly inhibited and was also associated with Tax 
mRNA inhibition, which is likely due interferon-medi-
ated restriction of viral expression. These results sug-
gested that SOCS1 had no effect on iNOS expression in 
HTLV-1 infected cells (Fig. 5d).
Treatment of HTLV-1 transformed cell lines, HuT102 
and MT4, with Ruxolitinib, a specific inhibitor of JAK1 
and JAK2, caused a decrease of both iNOS protein 
expression and NO production (Fig.  5e–g). To con-
firm that the increase in IRF-1 expression is leading to 
iNOS activation, we measured the expression of IRF-1 
and iNOS mRNA in MT4 cells transfected either with a 
control siRNA or with a specific siRNA directed against 
IRF-1 mRNA. The approximately 50% decrease of IRF-1 
mRNA was associated with a similar decrease in iNOS 
mRNA expression (Fig.  5h). We also established MT4 
and HUT102 cells that stably expressed specific shRNA 
directed against IRF-1 mRNA. As expected, the deple-
tion of IRF-1 expression correlated with a decrease in 
iNOS expression, indicating that IRF-1 is one of the tran-
scription factors involved in iNOS expression (Fig.  5i). 
Whether Tax directly activates the JAK/STAT pathway 
is still under investigation. However, data previously 
reported indicate that JAK/STAT might be induced at 
a later stage of infection by cytokines induced by Tax 
through the NF-κB pathway. Taken together, our results 
suggest that the NF-κB pathway has a central role in Tax-
mediated iNOS expression in HTLV-1 infected cells.
Discussion
ATLL is an aggressive fatal malignancy of CD4+ T-cells 
infected by HTLV-1 [51]. HTLV-1 induced leukemia/
lymphoma, like most cancers, is characterized by three 
major hallmarks: activation of proliferation, inhibition of 
tumor suppressors, and genetic instability. While in other 
cancers, these hallmarks can be established by driver 
mutations, HTLV-1 induced tumorigenesis is driven by 
the expression of the viral oncogene, HTLV-1 Tax, which 
induces a potent inflammatory response through the 
NF-κB pathway [52, 53]. Inflammatory mediators have 
been shown to contribute to the proliferation of pre-neo-
plastic cells, but it is still largely unknown whether or not 
they contribute to the accumulation of genomic damage, 
a driving force for tumorigenesis [30].
A role of Tax in inducing genomic damage has been 
under active investigation during the last decade. Tax 
targets proteins involved in DNA replication [54, 55], 
DNA damage and repair [26, 56], centrosome duplica-
tion [57], and cell cycle and cell division checkpoints 
[58–60]. The long period of latency and the low percent-
age of infected cells which are ultimately transformed 
suggest that Tax is able to induce random mutations. In 
this context, Tax has been shown to induce DNA dou-
ble strand breaks (DSB) [26], the most serious form of 
genomic damage. Since the NF-κB pathway is a critical 
determinant in Tax-mediated tumorigenesis [52], we 
wanted to delineate how inflammatory mediators con-
tribute to the accumulation of genomic damage. Here 
we show that in HTLV-1 infected cells, Tax activates the 
expression of iNOS, the enzyme that catalyzes the pro-
duction of NO in T-cells, macrophages and neutrophils. 
Moreover, we demonstrated that Tax induces DSBs 
through the induction of NO by the classical NF-κB 
and JAK/STAT pathways, which are implicated in the 
proliferation of HTLV-1 infected T-lymphocytes [61]. 
The activation of iNOS expression is at the intersection 
between these two pathways.
The central hypothesis of the study is that chronic 
inflammation induced by the NF-κB pathway induces 
DNA damage through activation of iNOS. Although sev-
eral transcription factors were reported to activate iNOS 
expression through inflammation-mediated activation 
[62], Tax activation of NO production through the NF-kB 
pathway provides a novel insight into the mechanisms 
regulating genomic instability and leading to ATLL. 
There is no doubt that Tax is required in the initials 
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Fig. 5 iNOS expression requires the activation of the JAK/STAT pathway by Tax. a iNOS expression correlates with IRF-1 expression in Tax express-
ing cells but not in Jurkat or CEM control cells. b Western blot analysis of key proteins in the JAK/STAT pathway, including JAK1, p-JAK1, and IRF1 in 
control CEM, non-induced JPX9, Tax-induced JPX9 (48 h with 40 μM CdCl2) and MT4 cells. Tax expression was also measured to show the specificity 
of expression in the HTLV-1 infected cell line and in the Tax inducible cell line. c TetOn Tax Jurkat cells were induced with doxycycline for 48 h and 
a Western blot analysis showing an increase of p-JAK1, p-STAT1 but not p-Tyk2 when Tax was induced. The percentage of expression was indicated 
on the top of each blot. d Real time measurement of SOCS1, iNOS and Tax mRNA in MT4 cells transfected with either control siRNA or specific siRNA 
directed against SOCS1 mRNA. e, f, g The expression of iNOS protein and NO production were reduced in HTLV-1 transformed cells lines (HuT102 
and MT4) treated 48 h with Ruxolitinib (7 nM), a JAK1 and JAK2 inhibitor, showing the specificity of the JAK/STAT pathway in iNOS expression. The 
percentage of expression of p-JAK1 and iNOS are shown below each panel of the figure. h MT4 cells transfected with control siRNA or with siRNA 
specifically directed against IRF-1 mRNA. Total RNA was extracted, and IRF-1 and iNOS mRNA was quantified by real time PCR. i Stable MT4 and 
HUT102 cell lines that express shRNA directed against control mRNA (GFP) or against IRF-1 mRNA were also tested for IRF-1 and iNOS expression by 
Western blot. The percent of expression for IRF-1 and iNOS are shown below each panel. Both experiments show a correlation between IRF-1 and 
iNOS expression.
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events, including genomic defects, which drive the leuke-
mogenic process in HTLV-1 infected cells.
Recent studies showed that other HTLV-1 viral pro-
teins [63] or other mechanisms [31] might be involved 
in NF-kB activation. Whether NF-kB constitutive activa-
tion in ATL cells requires the maintenance of Tax expres-
sion is still under intensive investigation. Nevertheless, 
HTLV-1 Tax remains a potent driver of NF-kB activation 
in the HTLV-1 infection model. On the other hand, the 
common concept that Tax is not detected in ATL cell 
lines does not mean that the protein is not expressed. Tax 
mRNA expression in ATL cell lines has been reported in 
multiple studies, and the NF-κB pathway might be acti-
vated with very low or intermittent levels of Tax which 
may be undetectable unless highly sensitive techniques 
are employed.
In HTLV1-mediated leukemogenesis as in other can-
cers, the driving events are associated with inactivation 
of tumor suppressors [64], which favors the accumulation 
of more cellular defects and contributes to the develop-
ment of cancer. If NO is produced at low concentrations 
in macrophages or activated T-cells, it promotes tumor 
cell proliferation, migration, invasion, and an envi-
ronment resistant to apoptosis [19]. Previous studies 
showed that NO produced by the tumor microenviron-
ment is involved in cancer development. However, the 
effects of cell intrinsic mechanisms of tumor promotion 
by NO have not been thoroughly studied. In particular, 
it is unclear how NO induces mutations and progressive 
genetic alterations via increased oxidative and nitrosative 
stress.
Tax is responsible for a wide range of oncogenic events 
associated with HTLV-1 infection [5]. It is still unclear 
whether DSBs are induced by Tax through the stimula-
tion of NO production alone. Indeed, 30–40% of the 
DSBs, typically found in Tax expressing cells, were still 
present after iNOS inhibition. This observation suggests 
that Tax may be able to induce DSBs through another 
mechanism, or that inhibition of iNOS is not complete. 
In this context, Tax may induce stalling of the DNA 
replication fork by targeting PCNA or topoisomerase I, 
two critical proteins implicated in DNA replication [65, 
66]. Tax has also been shown to increase the production 
of other reactive oxygen species, which are known to 
induce DNA damage [67]. Organic hydroperoxides, pre-
sent in cancer cells could also contribute to the observed 
phenotype. The effects of reactive oxygen species, other 
than NO, need to be investigated in future studies. To 
further delineate the mechanism of NO-mediated DSBs, 
future experiments will also be required to investigate the 
dynamic relationship between NO release and DSBs and 
test whether NO affects DNA by direct chemical interac-
tion or through another mechanism.
A recent publication showed that Tax attenuates DNA 
damage responses by inhibiting ATM through activation 
of phosphatase WIP1 [68]. In the study, the authors used 
UV-induced DNA damage response to investigate Tax 
activity. Given that Tax can be involved in both induc-
tion of DNA damage and inhibition of DNA repair, the 
present study aimed to investigate a mechanism by which 
Tax induces DSBs through inflammatory mediators in 
the absence of external DNA damage.
Although we found that NO induces DSBs and pro-
motes persistent genomic instability, this model only 
explains how HTLV-1 infected cells may acquire the 
oncogenic phenotype during infection. However, it does 
not provide an explanation for a requirement for sus-
tained NO production in HTLV-1 transformed cell lines, 
which have already acquired the transformed phenotype. 
Thus, NO might be required for oncogenic mechanisms 
other than the induction of DNA damage. NO is known 
to increase the nitrosylation of proteins: this posttrans-
lational modification may lead to either inactivation or 
activation of function. Therefore, nitrosylation of key 
proteins, implicated in T-lymphocyte proliferation, 
should be tested in order to further delineate the role of 
NO in transformed cell lines.
Conclusion
Genetic instability and DSBs in particular are believed to 
be a driving force for tumorigenesis. Here, we found that 
the release of nitric oxide was associated with an increase 
of DNA damage in HTLV-1 infection model, suggesting 
that NO might be an important source of genetic insta-
bility in HTLV-induced leukemia. Determination of the 
impact of NO on tumor formation in an ATLL model will 
help in the development of alternative strategies for ther-
apeutic applications of ATLL.
Methods
Cell lines, ATL patients, culture and drugs
All cell lines used in this study were obtained from the 
ATCC (American Type Culture Collection). HTLV-I 
transformed human T-cell lines MT2, MT4, and HuT102, 
control T-cell lines CEM and Jurkat, and Tax inducible 
transformed cell lines were all cultured in RPMI 1640 
(Sigma) with 10% fetal bovine serum (Sigma), supple-
mented with 2  mM glutamine, penicillin (100  U/ml), 
streptomycin (0.1 mg/ml), and amphotericin B (0.25 µg/
ml). JPX9 is a Jurkat subclone generated by stable trans-
fection of an inducible Tax expression vector driven by 
the metallothionein promoter (made by Prof Sugamura, 
Tohoku University, Sendai, Japan) [37]. TetOn-Tax is 
also a Jurkat subclone generated by introduction of an 
inducible TetOn Tax expression vector (made by Prof 
W C Greene, University of California, San Francisco, 
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USA) [38]. Peripheral blood mononuclear cells (PBMC) 
were isolated from healthy donors, purified on Ficoll, and 
CD4+ T-cells were separated using Easy Step Human 
CD4+ T Cell negative selection (STEMCELL Technolo-
gies). PBMCs from three ATLL patients with acute ATLL 
were also collected and frozen in 2010 under the patient’s 
consent. Details about ATLL patients’ samples are given 
in Table  1. 293T cells were maintained in Dulbecco’s 
modified Eagle medium, DMEM, supplemented with the 
same reagents as RPMI as well as 1 mM sodium pyruvate. 
Cells were maintained at 37°C in a humidified incubator 
with 5% CO2 concentration. 1400 W, a selective inhibitor 
of iNOS was purchased from Cayman chemicals and was 
used at the concentration of 7 nM for the time indicated 
in the figure legends. cPTIO ((2-(4-Carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide), which is 
an NO scavenger, was used at a concentration of 100 μM 
(Santa Cruz Biotechnologies).
Co‑culture of MT2 and PBMC
Lethally irradiated MT2 cells (10,000  cGy) were co-
cultured with fresh PBMCs from healthy donors (ratio 
1–10, MT2/PBMC). The PBMCs were cultured in com-
plete RPMI (10% FBS) with PHA 1 μg/ml and 50 units/
ml IL-2. The freshly infected PBMC were monitored 
side by side with irradiated MT2, non-irradiated MT2 
cells, and uninfected PBMCs for 2–3  weeks, and RNA 
was extracted for real time measurements of iNOS and 
GAPDH mRNA.
Plasmids, lentiviral vectors and transfection methods
The vector TetOn-pLKO1 puro, used to induce the 
expression of iNOS shRNA, was purchased from Adgene 
(plasmid 21915) [69]. The sequences of oligos cloned into 
AgeI and EcoRI sites in the vector to create the respec-
tive shRNAs are listed in Table  2. Lentiviral particles 
expressing shRNAs were prepared by transfecting 293T 
cells with TetOn-pLKO1-shRNA, HIV-gag-pol (10  µg) 
and VSV-G (10  µg) expressing plasmids using calcium 
phosphate. Supernatant was collected at 24, 48 and 72 h, 
and lentiviral particles were concentrated by ultracen-
trifugation. To deplete the expression of IRF-1, pLKO-1 
puro vectors stably expressing five different shRNA that 
target IRF-1 mRNA were provided by the Genome Insti-
tute at Washington University. The target sequences of 
these shRNAs are given in Table 2. The determination of 
virus titer by the infection of control cells gives the num-
ber of viruses required to infect target cells at an MOI of 
1. Lentiviral particles were used to transduce MT4 cells 
in the presence of polybrene 12  μg/ml, and cells were 
Table 2 Sequences of shRNA used to deplete the corresponding targets, and primers used for real time PCR
pLKO-1 shRNA IRF-1 target sequences
 IRF-1 CGTGTGGATCTTGCCACATTT
 IRF-1 CCTCTGTCTATGGAGACTTTA
 IRF-1 GCAGATTAATTCCAACCAAAT
 IRF-1 AGATGCTAAGAGCAAGGCCAA
 IRF-1 GCGTGTCTTCACAGATCTGAA
TetOn-pLKO-1 shRNA
 hiNOS Forward: 5′-CCGGAACATTGCTGTGCTCCATAGTCTCGAGACTATGGAGCACAGCAATGTTTTTTG-3’  
 hiNOS Reverse: 5′-AATTCAAAAAAACATTGCTGTGCTCCATAGTCTCGAGACTATGGAGCACAGCAATGTT-3’
 GFP Forward: 5′-CCGGCAGCCACAACGTCTATATCATCTCGAGATGATATAGACGTTGTGGCTGTTTTTG-3’
 GFP Reverse: 5′-AATTCAAAAACAGCCACAACGTCTATATCATCTCGAGATGATATAGACGTTGTGGCTG-3’
Real time PCR primers
 hGAPDH Forward: 5′-GTGAAGGTCGGAGTCAACGG-3′
Reverse: 5′-AGTGATGGCATGGACTGTGG-3′
 hiNOS Forward: 5′-ACAACAAATTCAGGTACGCTGTG-3′
Reverse: 5′-TCTGATCAATGTCATGAGCAAAGG-3′
 IκBα Forward: 5′-TGTCTACACTTAGCCTCTATC-3′
Reverse: 5′-TCTGTGAACTCCGTGAACTC-3′
 IRF-1 Forward: 5′-GAACTCCCTGCCAGATATCGAG-3′
Reverse: 5′-TGCTCTTAGCATCTCGGCTGG-3′
 SOCS1 Forward: 5′-TTTTTCGCCCTTAGCGTGA-3′
Reverse: 5′-AGCAGCTCGAAGAGGCAGTC-3′
 Tax Forward: 5′-CGGATACCCAGTCTACGTGT-3′
Reverse: 5′-GAGCCGATAACGCGTCCATCGATG-3′
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selected in puromycin (2 μg/ml) starting 48 h later. The 
S-Tag Tax-1 plasmid was a generous gift from O. John 
Semmes [70]. The S-Tag Tax-1 M22 expression plasmid 
contains the Tax M22 mutation defective in NFκB activa-
tion [71]. S-Tag Tax-2 plasmid was constructed by ampli-
fying the open reading frame of Tax from BC20.2 [72] 
and was inserted into pTriEx™-4 Neo vector (Novagene, 
Madison, WI, USA) in-frame with the amino-terminal 
S-tag. The M47 mutation was amplified with internal 
primers from pACH M47 and was swapped with Tax1 
in S-Tag Tax1 to create S-Tag Tax1 M47. Plasmid struc-
tures were confirmed via sequence analysis. The plasmid 
phiNOS-Luc expressing the luciferase gene under the 
control of hiNOS promoter was a gift from Dr. David A. 
Geller (Director, UPMC Liver Cancer Center, Univer-
sity of Pittsburgh) [47]. κB-Luc expressing the luciferase 
gene under the control of 5 κB responsive elements was 
a gift from Dr. D Piwnica-Worms [73]. The plasmid pRL 
expressing the renilla luciferace under the promoter of 
thymidine kinase was used for transfection efficiency and 
for normalizing the luciferase activities (Promega). The 
transfection of 293T and Hela cells was performed using 
TransIT reagent based on the manufacture’s recommen-
dations (Mirus Bio), and the luciferase activities were 
calculated using a dual luciferase solution. Jurkat and 
MT4 cells were transfected by electroporation using the 
BTX electroporation system 600. siRNA control or that 
directed against IRF-1 or SOCS1 mRNA were purchased 
from Santa Cruz Biotechnology (SC-35706, SC-40997).
Real time RT‑PCR
The expression of human iNOS, IκBα, IRF-1, SOCS1 and 
HTLV-1 Tax was quantified by real time PCR using Bio-
rad iCycler. Briefly, the total mRNA of HTLV-1 positive 
and negative cell lines was extracted by Trizol, DNase-I 
treated and reverse-transcribed using the High capacity 
RNA to cDNA kit (Applied Bioscience) as recommended 
by the manufacturer. Quantitative reverse transcriptase 
PCR (40 cycles) was performed in a total of 20 μl con-
taining the iQ Sybr Green supermix reagent (Bio-rad), 
deionized water, primers at 0.5  μM each and cDNA as 
recommended by the manufacturer. Human GAPDH was 
used as an internal amplification control. Relative expres-
sion was determined by the delta delta Ct method. The 
fold change = 2−CT.
Western blot
Cell extracts were prepared using RIPA lysis buffer 
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% 
SDS, 0.5% DOC and protease inhibitor cocktail (Roche). 
Proteins were quantified by Bradford assay and sepa-
rated by SDS PAGE, transferred to PVDF membranes 
and detected using the standard protocol for Western 
Blot. Primary antibodies used in this study were directed 
against the following proteins: iNOS SC-651 (Santa 
Cruz), Actin (SC-1615), and Tax mouse monoclonal 
(NIH AIDS Reagent Program, HTLV-I Tax Hybridoma 
(168B17), p-JAK1 (SC-16773), JAK (SC-277), p-STAT1 
(SC-7988), STAT1 (SC-592), IRF1 (SC-497), p-Chk2 (SC-
16279), p-H2AX (Biolegend 613402), Chk2 (SC-2662p), 
H2AX (Biolegend 613301) p100/p52 (Millipore 05-361), 
p50 (SC-1190) and S-Tag (Millipore MAC 112). Signals 
were detected using the ChemiDoc XRC from Bio-Rad.
Immunocytofluorescence staining and microscopy
T-cell lines were cytospun onto slides at 800  rpm for 
5  min. The cells were then fixed in 3.7% paraformal-
dehyde (PFA) for 15  min at RT, washed with PBS, per-
meabilized on ice for 5 min with 0.5% Triton X-100, and 
blocked for 1 h in PBS with 0.5% gelatin and 0.25% bovine 
serum albumin at room temperature. Slides were next 
incubated with anti-iNOS and anti-p-H2AX antibodies 
at 1/200 in PBS for 2 h, washed three times in PBS-0.2% 
gelatin for 10  min each time, and incubated with Alexa 
Fluor 488-conjugated goat anti-rabbit secondary anti-
body and Alexa Fluor 596-conjugated goat anti-mouse 
secondary antibody (Molecular Probes, Invitrogen) in 
PBS-0.2% gelatin for 1 h at room temperature. Cells were 
washed three times in PBS-0.2% gelatin for 10 min each 
time and mounted using DABCO mounting medium 
(2.5% DABCO from Sigma, 200  mM Tris–HCl pH 8.6 
and 90% glycerol). Fluorescent images were captured 
using a Nikon Eclipse Tis epifluorescence microscope 
and the NIS elements software (Nikon). The images were 
collected by using the objectives 20X and 40X, and the 
number of DNA Double-Strand Breaks (DSB) foci and 
the quantification of fluorescence intensity was per-
formed using the object count module in NIS elements.
Comet assay
Comet Assay is a single cell electrophoresis technique 
that provides a simple and effective method for evaluat-
ing DNA damage in cells. NO and its reactive products 
induce DNA modifications that start as single-strand 
breaks, which result in DNA double-strand breaks. We 
performed the Comet Assay alkaline method that detects 
both single-strand and double-strand breaks based on 
the manufacturer’s protocol (Trevigen).
Flow cytometry
Intracellular staining of NO pools was performed accord-
ing to the manufacturer’s instructions (Cayman) with 
4,5-Diaminofluorescein Di-acetate (DAF-2DA). Annexin 
V/Propidium iodide kit (BD Biosciences) was used to 
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measure apoptosis in cells treated with iNOS inhibitor, or 
cells expressing shRNA according to the manufacturer’s 
instructions. Cells were analyzed by FACS Caliber.
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